Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT ID: NCT04589845
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
920 participants
INTERVENTIONAL
2021-01-18
2032-09-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NCT03108131
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
NCT01885195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC)
Participants with metastatic or advanced solid tumors, with the exception of non-small cell lung cancer (NSCLC), will receive entrectinib once daily (QD) in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) ≥ 1.51 square meter (m\^2). The total dose of daily entrectinib administration for pediatric participants with BSA \< 1.51 m\^2 will be lower.
Entrectinib
Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).
Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors
Participants with metastatic or advanced solid tumors will receive entrectinib, QD in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA ≥ 1.51 m\^2. The total dose of daily entrectinib administration for pediatric participants with BSA \< 1.51 m\^2 will be lower.
Entrectinib
Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).
Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC)
Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg, orally, twice a day (BID), taken with food, in repeated 28-day cycles.
Alectinib
Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).
Cohort D: TMB-high Tumors
Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged ≥ 18 years, and 15 milligrams per kilogram (mg/kg) (maximum 1200 mg) for participants aged \< 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed for enrollment.
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors
Participants with metastatic or advanced solid tumors will receive ipatasertib orally, QD at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kilograms (kg), 300 mg for participants ≥ 35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed for enrollment.
Ipatasertib
For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors
Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.
Note: Cohort F has been closed as of protocol version 7 because enrollment and participant follow-up have been completed.
Trastuzumab emtansine
Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Cohort H: PIK3CA Multiple Mutant-positive Tumors
Participants with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) multiple mutant-positive tumors will receive inavolisib (GDC-0077) QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles. Note: Cohort H has been closed for enrollment.
Inavolisib
GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Cohort I: BRAF Class II Mutant or Fusion-positive Tumors
Participants with proto-oncogene B-Raf (BRAF) class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib, PO, BID with adequate water (more than 200 milliliters \[mL\]). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed for enrollment.
Belvarafenib
Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Cohort J: BRAF Class III Mutant-positive Tumors
Participants with BRAF class III mutant-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib PO BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort J has been closed for enrollment.
Belvarafenib
Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Cohort K: Rearranged During Transfection (RET) Fusion-positive Tumors (Excluding NSCLC)
Participants with RET fusion-positive tumors will self-administer pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days). Note: Cohort K has been closed for enrollment.
Pralsetinib
Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Cohort L: KRAS G12C-positive Tumors (Excluding NSCLC and Colorectal Cancer [CRC])
Participants with kirsten rat sarcoma virus (KRAS) G12C-positive tumors will self-administer divarasib (GDC-6036) orally at home (except on clinic days).
Divarasib
Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).
Cohort M: Ataxia-telangiectasia Mutated (ATM) Loss of Function (LOF) Tumors
Participants with ATM LOF tumors will self-administer camonsertib orally at home (except on clinic days).
Camonsertib
Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Cohort N: SETD2 LOF Tumors
Participants with methyltransferase SET (Su(var) 3-9) Enhancer of zest and Trithorax) domain-containing 2 (SETD2) LOF tumors will self-administer camonsertib orally at home (except on clinic days).
Camonsertib
Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Entrectinib
Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).
Entrectinib
Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).
Alectinib
Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
Ipatasertib
For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
Trastuzumab emtansine
Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Inavolisib
GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Belvarafenib
Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Pralsetinib
Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Divarasib
Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).
Camonsertib
Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease as defined by RECIST v1.1, RANO, or INRC
* Performance status as follows: Participants aged ≥ 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to \< 18 years: Karnofsky score ≥ 50%; Participants aged \< 16 years: Lansky score ≥ 50%
* For participants aged ≥ 18 and \< 18 years: adequate hematologic and end-organ function
* Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
* Adequate recovery from most recent systemic or local treatment for cancer
* Life expectancy ≥ 8 weeks
* Ability to comply with the study protocol, in the investigator's judgment
Exclusion Criteria
* Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
* Whole brain radiotherapy within 14 days prior to start of study treatment
* Stereotactic radiosurgery within 7 days prior to start of study treatment
* Pregnant or breastfeeding, or intending to become pregnant during the study
* History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
* Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
* History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Cancer Center
Daphne, Alabama, United States
Western Regional Medical Center at Cancer Treatment Centers of America
Goodyear, Arizona, United States
City of Hope National Medical Center
Duarte, California, United States
Kaiser Permanente Los Angeles
Los Angeles, California, United States
USC Norris Cancer Center
Los Angeles, California, United States
Hoag Memorial Hospital
Newport Beach, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
University of California at San Francisco
San Francisco, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Christiana Care Health Srvcs
Newark, Delaware, United States
University of Florida
Gainesville, Florida, United States
Miami Cancer Institute of Baptist Health, Inc.
Miami, Florida, United States
Ocala Oncology Center
Ocala, Florida, United States
University Cancer & Blood Center, LLC
Athens, Georgia, United States
St. Alphonsus
Boise, Idaho, United States
Midwestern Regional Med Center
Zion, Illinois, United States
Horizon Oncology Research, Inc.
Lafayette, Indiana, United States
New England Cancer Specialists
Scarborough, Maine, United States
Maryland Hematology & Oncology. P.A.
Silver Spring, Maryland, United States
St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Metro-Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States
Washington University
St Louis, Missouri, United States
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
Billings, Montana, United States
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada - Eastern Avenue
Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
National Translational Research Group
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
New York Cancer and Blood Specialists - Setauket Medical Oncology
Port Jefferson Station, New York, United States
Montefiore Einstein Center for Cancer Care
The Bronx, New York, United States
Eastchester Center for Cancer Care
The Bronx, New York, United States
Barrett Cancer Center
Cincinnati, Ohio, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, United States
Providence Portland Medical Center
Portland, Oregon, United States
Consultants in Medical Oncology and Hematology
Broomall, Pennsylvania, United States
Alliance Cancer Specialists
Horsham, Pennsylvania, United States
Virginia Cancer Specialists - Leesburg
Leesburg, Pennsylvania, United States
Cancer Treatment Centers of America
Philadelphia, Pennsylvania, United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
PRISMA Health - Greenville
Greenville, South Carolina, United States
The West Clinic
Germantown, Tennessee, United States
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Texas Oncology - Central South
Austin, Texas, United States
Mary Crowley Medical Research Center
Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Cook Childrens Medical Center
Fort Worth, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Texas Oncology- Northeast Texas
Tyler, Texas, United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Kinghorn Cancer Centre
Darlinghurst, New South Wales, Australia
Sydney Children's Hospital
Randwick, New South Wales, Australia
Royal Darwin Hospital
Tiwi, Northern Territory, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Royal Children's Hospital
Parkville, Victoria, Australia
Cliniques Universitaires St-Luc
Brussels, , Belgium
GHdC Site Les Viviers
Charleroi, , Belgium
UZ Antwerpen
Edegem, , Belgium
UZ Gent
Ghent, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sírio-Libanês
São Paulo, São Paulo, Brazil
Hospital Sírio-Libanês
São Paulo, São Paulo, Brazil
Hospital A. C. Camargo
São Paulo, São Paulo, Brazil
Clínica Onco Star - Rede D'Or
São Paulo, São Paulo, Brazil
BC Cancer Vancouver
Vancouver, British Columbia, Canada
London Health Sciences Centre · Victoria Hospital
London, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
McGill University Health Center
Montreal, Quebec, Canada
Beijing Cancer Hospital
Beijing, , China
Beijing Children's Hospital, Capital Medical University
Beijing, , China
The First Hospital of Jilin University
Changchun, , China
Jilin Cancer Hospital
Changchun, , China
West China Hospital - Sichuan University
Chengdu, , China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, , China
Shanghai East Hospital
Shanghai, , China
Zhongshan Hospital Fudan Unvierstiy
Shanghai, , China
Tianjin Cancer Hospital
Tianjin, , China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, , China
Aarhus Universitetshospital
Aarhus N, , Denmark
Rigshospitalet
København Ø, , Denmark
Institut Bergonie
Bordeaux, , France
Centre Oscar Lambret
Lille, , France
Centre Leon Berard
Lyon, , France
Hopital de la Timone
Marseille, , France
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, , France
Institut de Cancerologie Gustave-Roussy (IGR)
Villejuif, , France
Uniklinik Essen
Essen, , Germany
Georg-August-Uniklinik
Göttingen, , Germany
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
Hamburg, , Germany
Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie
Hanover, , Germany
SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III
Heilbronn, , Germany
Praxis für Hämatologie, Onkologie und Palliativmedizin
Mönchengladbach, , Germany
Klinikum der Universität München, Campus Großhadern
München, , Germany
Universtitätsklinikum Ulm
Ulm, , Germany
Uniklinikum, Comprehensive Cancer Center Mainfranken
Würzburg, , Germany
Hong Kong Children's Hospital
Hong Kong, , Hong Kong
Prince of Wales Hospital
Shatin, , Hong Kong
Rambam Health Care Campus
Haifa, , Israel
Hadassah University Hospital - Ein Kerem
Jerusalem, , Israel
Rabin MC
Petah Tikva, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Sourasky / Ichilov Hospital
Tel Aviv, , Israel
Istituto Nazionale Tumori Fondazione G. Pascale
Napoli, Campania, Italy
Ospedale Pediatrico Bambino Gesù - IRCCS
Rome, Lazio, Italy
Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, Italy
Asst Degli Spedali Civili Di Brescia
Brescia, Lombardy, Italy
Irccs Istituto Nazionale Dei Tumori (Int)
Milan, Lombardy, Italy
Istituto Nazionale Tumori di Milano
Milan, Lombardy, Italy
Dipartimento di Scienze Pediatriche Adolescenza
Turin, Piedmont, Italy
Azienda Ospedaliera Meyer
Florence, Tuscany, Italy
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
Siena, Tuscany, Italy
National Cancer Center Hospital East
Chiba, , Japan
Kindai University Hospital
Osaka, , Japan
National Cancer Center Hospital
Tokyo, , Japan
Auckland City Hospital, Cancer and Blood Research
Auckland, , New Zealand
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gdansk, , Poland
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
Warsaw, , Poland
IPO do Porto
Porto, , Portugal
PanOncology Trials
San Juan, , Puerto Rico
National University Hospital
Singapore, , Singapore
National Cancer Centre
Singapore, , Singapore
Medical Oncology Centre of Rosebank
Johannesburg, , South Africa
Seoul National University Bundang Hospital
Gyeonggi-do, , South Korea
Seoul National University Hospital- Adult Site
Seoul, , South Korea
Seoul National University Hospital- Pediatric Site
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center- Adult Site
Seoul, , South Korea
Samsung Medical Center- Pediatric Site
Seoul, , South Korea
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, , Spain
Hospital Infantil Universitario Nino Jesus
Madrid, , Spain
Clinica Universidad de Navarra Madrid
Madrid, , Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
START Madrid. Centro Integral Oncologico Clara Campal
Madrid, , Spain
Hospital Universitario la Fe
Valencia, , Spain
Universitätsspital Basel (USB)
Basel, , Switzerland
Ospedale Regionale di Bellinzona Medizin Onkologie
Bellinzona, , Switzerland
Inselspital, Klinik und Poliklinik für Medizinische Onkologie
Bern, , Switzerland
Unversitätsspital Zürich
Zurich, , Switzerland
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital-Linkou
Taoyuan, , Taiwan
National Taiwan University Hospital
Zhongzheng Dist., , Taiwan
Beatson West of Scotland Cancer Centre
Glasgow, , United Kingdom
University College London Hospital
London, , United Kingdom
Guys and St Thomas NHS Foundation Trust, Guys Hospital
London, , United Kingdom
Royal Manchester Children?s Hospital
Manchester, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: BO41932 https://forpatients.roche.com/
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-001847-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023-507418-28-00
Identifier Type: CTIS
Identifier Source: secondary_id
BO41932
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.